top of page

Available Trials 

Advanced/Metastatic
Non-Small Cell Lung Cancer

TROPION-Lung17 will measure the efficacy and safety of datopotamab deruxtecan (Dato-DXd) compared with docetaxel in patients with trophoblast cell surface protein 2 (TROP2) positive advanced or metastatic lung cancer without actionable genomic alterations (AGA).

Metastatic Non-Small Cell Lung Cancer:

Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.


Non-Small Cell Lung Cancer

The purpose of this study is to collect blood samples from a large number of individuals with cancer to create a database for researchers to use in future studies. Researchers may use this database to discover new ways to detect and treat cancer and other diseases. Future studies may use stored blood samples to discover how genes affect health and disease.

Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma:

This study is designed to assess the levels of drug exposure following treatment with tislelizumab administered as a subcutaneous (SC) injection compared to intravenous infusion (IV) as first-line therapy in adults with gastric or gastroesophageal junction (GEJ) that is locally advanced and cannot be surgically removed or has spread from the stomach to other areas of the body. Approximately 351 patients will be participating in this study. The study is composed of a screening period, a treatment period, and a follow-up period.

North - 3440 Depaul Ln Ste 201 Bridgeton, MO 63044 - 314-291-3312

South - 10004 Kennerly Rd Ste 137a St. Louis, MO 63128 - 314-842-7301

West - 226 S Woods Mill Rd Ste 45W Chesterfield, MO 63017 - 314-579-0051

bottom of page